Connect with us

Hi, what are you looking for?

Health Care Sector

CIGB-258 and Itolizumab Show Success in COVID-19 Treatment

CIGB-258 and Itolizumab (Anti-CD6) now being used in Cuba to treat COVID-19 infection. Photo by Polina Tankilevitch

Two more drugs, CIGB-258 and Itolizumab (Anti-CD6), manufactured by the Center for Genetic Engineering and Biotechnology (CIGB) have been added to Cuba’s arsenal of drugs in the fight against COVID-19.

Dr. Francisco Duran, the National Director of Epidemiology at the Ministry of Public Health told the media on Friday that the two drugs have demonstrated success in the treatment of severe COVID-19 cases. He said 52 critically ill patients have been treated with the drugs resulting in a 92% survival rate.

CIGB-258 is a peptide vaccine designed to treat chronic inflammation in patients with rheumatoid arthritis.

Itolizumab is a humanized anti-CD6 monoclonal antibody.

Advertisement. Scroll to continue reading.

Although the drugs do not “cure” COVID-19, they have shown success in reducing hyper-inflammation, a symptom of patients in the critical stages of COVID-19.

Cuba is also using blood plasma from recovered patients to help patients in serious condition.

Both drugs have received approval for use from Cuba’s regulatory body, the Center for State Control of Drugs.

These drugs have demonstrated high recovery rates but are not a “cure” for COVID-19, as no cure-all drug has been found yet. The drugs have few side effects and do not damage internal organs.

Advertisement. Scroll to continue reading.

As of today, the Ministry of Health reports that there have been 1,963 cases of COVID-19, 1,709 recoveries, and 82 deaths since the first appearance of the infection on the Island.

Related News:

Health Care Sector

Cuba and China are working together to develop a new vaccine called the PanCorona which will be effective against new variants of COVID-19. The...

Health Care Sector

Cuba has registered its fourth COVID-19 vaccine to undergo clinical trials. The two new vaccines are known as the Mambisa (CIGB 669) and Abdala...

Health Care Sector

Itolizumab, a monoclonal antibody developed by the Center of Molecular Immunology (CIM) in collaboration with Biocon, India’s largest pharmaceutical company, received authorization to begin...

Health Care Sector

His Excellency Ambassador Antony Stokes LVO attended a presentation at the Center for Genetic Engineering and Biotechnology (CIGB) to learn of the progress of...

error: This content is copyright protected.